149 related articles for article (PubMed ID: 8334840)
1. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
[No Abstract] [Full Text] [Related]
2. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
[TBL] [Abstract][Full Text] [Related]
3. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
5. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
6. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Baba M; Kimura K; Suda T; Yagihashi S;
J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
[No Abstract] [Full Text] [Related]
7. [Epalrestat].
Hotta N
Nihon Rinsho; 1997 Nov; 55 Suppl():204-11. PubMed ID: 9434468
[No Abstract] [Full Text] [Related]
8. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
11. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
[TBL] [Abstract][Full Text] [Related]
13. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
14. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
Matsuoka K; Sakamoto N; Akanuma Y; Hotta N; Shichiri M; Toyota T; Oka Y; Kawamori R; Shigeta Y;
Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S263-8. PubMed ID: 17599629
[TBL] [Abstract][Full Text] [Related]
15. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
16. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
17. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
18. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.
Arezzo JC; Rosenstock J; Lamoreaux L; Pauer L
BMC Neurol; 2008 Sep; 8():33. PubMed ID: 18796160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]